Cowen raised the price target for the Exagen Inc. (NASDAQ:XGN) stock to ‘an Outperform’. The rating was released on October 15, 2021, according to finviz. The research report from KeyBanc Capital Markets has initiated the stock to Overweight, with a price target set at $32. The stock was initiated by BTIG Research, who disclosed in a research note on October 08, 2020, to Buy and set the price objective to $18. In their research brief published June 02, 2020, Cantor Fitzgerald analysts resumed the Exagen Inc.